Calidi Biotherapeutics Inc.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing a new generation of targeted immunotherapies for solid tumors. Their mission is to arm the immune system to kill cancer by using 'off-the-shelf' stem cells to deliver viral payloads that kill cancer cells locally and supercharge the immune system to fight metastatic disease. Their platforms help the immune system recognize and attack 'hot' tumors, aiming to redefine cancer treatment.

Products & Services

Targeted Immunotherapies:Innovative therapies designed to attack solid tumors and train the immune system to hunt down cancer cells throughout the body.

CLD-201:A targeted antitumor virotherapy for solid tumors, recently cleared by the FDA for an IND application.

Systemic Oncolytic Platform:Features CD55-enhanced expression and IL-15 superagonist payload, presented at the ASCO Annual Meeting.

Specialties

Targeted Immunotherapies Antitumor Virotherapies Oncology Solid Tumor Treatments Systemic Oncolytic Platforms genetic medicine delivery oncology complex disease treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6000000 MR: - FA: 6.0 million FAN: 6000000	D: 2026-03-09 FD: 2026-03-09	1 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 5200000 MR: - FA: $5.2 million FAN: 5200000	D: 2026-03-06 FD: 2026-03-06	1 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6900000 MR: - FA: 6.9 million FAN: 6900000	D: 2025-08-21 FD: 2025-08-21	2 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 6000000 MR: - FA: $6 million FAN: 6000000	D: 2025-08-20 FD: 2025-08-20	2 investors
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4600000 MR: - FA: approximately $4.6 million FAN: 4600000	D: 2025-07-09 FD: 2025-07-09	-
6	RT: Registered Direct Offering and Private Placement T: - FT: Registered Direct Offering and Private Placement	A: 3900000 MR: - FA: 3.9 million FAN: 3900000	D: 2025-03-31 FD: 2025-03-31	1 investors
7	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 3900000 MR: - FA: $3.9 million FAN: 3900000	D: 2025-03-28 FD: 2025-03-28	1 investors
8	RT: Public Offering T: - FT: Public Offering	A: 4250000 MR: - FA: approximately $4.25 million FAN: 4250000	D: 2025-01-10 FD: 2025-01-10	-
9	RT: Public Offering T: - FT: Public Offering	A: 7500000 MR: - FA: 7.5 million FAN: 7500000	D: 2024-11-15 FD: 2024-11-15	-
10	RT: Public Offering T: - FT: Public Offering	A: 7500000 MR: - FA: 7.5 million FAN: 7500000	D: 2024-11-14 FD: 2024-11-14	-
11	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 2000000 MR: - FA: Approximately $2 million FAN: 2000000	D: 2024-10-23 FD: 2024-10-23	1 investors
12	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2100000 MR: - FA: 2.1 million FAN: 2100000	D: 2024-05-31 FD: 2024-05-31	-
13	RT: Public Offering T: - FT: Public Offering	A: 6100000 MR: - FA: 6.1 million FAN: 6100000	D: 2024-04-19 FD: 2024-04-19	1 investors
14	RT: Public Offering T: - FT: Public Offering	A: 6100000 MR: - FA: approximately $6.1 million FAN: 6100000	D: 2024-04-16 FD: 2024-04-16	-
15	RT: Grant T: - FT: Grant	A: 5300000 MR: - FA: $5.3 million FAN: 5300000	D: 2024-03-11 FD: 2024-03-11	1 investors
16	RT: Series B T: - FT: Series B	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2023-06-23 FD: 2023-06-23	2 investors

Underwritten Public Offering Latest

2026-03-09

$6.0M

1 investor (Pro only)

Underwritten Public Offering 2026-03-06

$5.2M

Underwritten Public Offering 2025-08-21

$6.9M

View 15 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric Poma

Chief Executive Officer and Director

A

Andrew Jackson

Chief Financial Officer

A

Antonio F. Santidrian

Chief Scientific Officer and Head of Technical Operations

G

Guy Travis Clifton

Chief Medical Officer

View 1 more team members with Pro

Unlock Full Team Directory

Recent News